Global Trends of Early, Middle, and Late-Onset Lung Cancer From 1990 to 2021: Results From the Global Burden of Disease Study 2021

Overview

Journal Cancer Med

Date 2025 Feb 7

PMID 39918236

Authors

Zongyuan Li

Cheng Yu

Jianqi Hao

Nanzhi Luo

Haoning Peng

Jian Zhang

Qiang Pu

Lunxu Liu

Affiliations

Soon will be listed here.

Abstract

Background: Although the global burden of lung cancer has generally declined in recent decades, the variation in onset age-related trends remains insufficiently explored. In the current study, we aimed to systematically evaluate the most update temporal trends in incidence, mortality and DALYs of early, middle, and late-onset lung cancer (EOLC, MOLC, and LOLC) from 1990 to 2021, with stratifications of gender, location, and socio-demographic development.

Methods: We retrieved cross-sectional data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021. The global, regional, and national burden of lung cancer from 1990 to 2021 was evaluated primarily by age-standardized rates of incidence (ASIR), mortality (ASMR), and DALYs (ASDR). Joinpoint regression analysis was employed to assess temporal trends and turning point years. Frontier analysis was applied to examine the lowest achievable DALYs, and cross-country inequalities were evaluated sing the slope index of inequality (SII) and concentration index. We also forecasted the burden from 2022 to 2035.

Results: The global ASIR of EOLC decreased from 4.81 per 100,000 in 1990 to 3.13 in 2021 (AAPC: -1.38, 95% confidence interval [CI]: -1.53 to -1.22, p < 0.001), with a steeper decline in males (AAPC: -1.79) compared to females (AAPC: -0.63). MOLC incidence also declined from 92.77 to 72.47 per 100,000 (AAPC: -0.81, 95% CI: -0.9 to -0.73, p < 0.01), while LOLC demonstrated a slight increase from 195.39 to 225.8 per (AAPC: 0.43, 95% CI: 0.37 to 0.5, p < 0.01). Notably, LOLC in females showed a consistent rise in incidence rate (AAPC: 1.13, 95% CI: 1.05 to 1.21, p < 0.01). In contrast to EOLC and MOLC, 11, 10, and 9 out of 21 GBD regions showed a rising trend for ASIR, ASMR, and ASDR of LOLC, respectively. East Asia showed the steepest increase in ASIR (from 229.26 in 1990 to 375.90 in 2021, AAPC = 1.6, 95% CI: 1.31 to 1.89, p < 0.001) of LOLC. Moreover, according to socio-demographic index (SDI) quintiles, the middle SDI region demonstrated the largest rise in ASIR of LOLC. Frontier analysis revealed that countries with higher SDIs had a greater capacity for reducing lung cancer burdens. Cross-country inequalities of lung cancer burden in females were found to improve much slower than in males. The projections implied that, although lung cancer would generally decline in the next decade, the incidence, mortality, and DALY rates of LOLC in females might remarkably increase.

Conclusions: The global incidence, mortality, and DALY rates of lung cancer showed a general decline from 1990 to 2021. However, concerning trends of LOLC burden, especially among females and in specific regions or countries, were observed in this study. This study could help to guide more targeted prevention and intervention strategies for lung cancer control.

References

Doll R, Peto R, Boreham J, Sutherland I . Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ. 2004; 328(7455):1519. PMC: 437139. DOI: 10.1136/bmj.38142.554479.AE. View

Lin L, Li Z, Yan L, Liu Y, Yang H, Li H . Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990-2019. J Hematol Oncol. 2021; 14(1):197. PMC: 8607714. DOI: 10.1186/s13045-021-01213-z. View

Thun M, Peto R, Boreham J, Lopez A . Stages of the cigarette epidemic on entering its second century. Tob Control. 2012; 21(2):96-101. DOI: 10.1136/tobaccocontrol-2011-050294. View

Shi J, Shiraishi K, Choi J, Matsuo K, Chen T, Dai J . Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population. Nat Commun. 2023; 14(1):3043. PMC: 10220065. DOI: 10.1038/s41467-023-38196-z. View

. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024; 403(10440):2162-2203. PMC: 11120204. DOI: 10.1016/S0140-6736(24)00933-4. View

. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024; 403(10440):2100-2132. PMC: 11126520. DOI: 10.1016/S0140-6736(24)00367-2. View

. Quitting smoking among adults--United States, 2001-2010. MMWR Morb Mortal Wkly Rep. 2011; 60(44):1513-9. View

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

Riebler A, Held L . Projecting the future burden of cancer: Bayesian age-period-cohort analysis with integrated nested Laplace approximations. Biom J. 2017; 59(3):531-549. DOI: 10.1002/bimj.201500263. View

10.

Malhotra J, Malvezzi M, Negri E, La Vecchia C, Boffetta P . Risk factors for lung cancer worldwide. Eur Respir J. 2016; 48(3):889-902. DOI: 10.1183/13993003.00359-2016. View

11.

Howlader N, Forjaz G, Mooradian M, Meza R, Kong C, Cronin K . The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med. 2020; 383(7):640-649. PMC: 8577315. DOI: 10.1056/NEJMoa1916623. View

12.

Wagner B, Cleland K . Using autoregressive integrated moving average models for time series analysis of observational data. BMJ. 2023; 383:2739. DOI: 10.1136/bmj.p2739. View

13.

Murray C . Findings from the Global Burden of Disease Study 2021. Lancet. 2024; 403(10440):2259-2262. DOI: 10.1016/S0140-6736(24)00769-4. View

14.

Shi Y, Au J, Thongprasert S, Srinivasan S, Tsai C, Khoa M . A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014; 9(2):154-62. PMC: 4132036. DOI: 10.1097/JTO.0000000000000033. View

15.

Ragavan M, Patel M . The evolving landscape of sex-based differences in lung cancer: a distinct disease in women. Eur Respir Rev. 2022; 31(163). PMC: 9488944. DOI: 10.1183/16000617.0100-2021. View

16.

Zhao J, Xu L, Sun J, Song M, Wang L, Yuan S . Global trends in incidence, death, burden and risk factors of early-onset cancer from 1990 to 2019. BMJ Oncol. 2025; 2(1):e000049. PMC: 11235000. DOI: 10.1136/bmjonc-2023-000049. View

17.

Leiter A, Veluswamy R, Wisnivesky J . The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol. 2023; 20(9):624-639. DOI: 10.1038/s41571-023-00798-3. View

18.

Kim H, Fay M, Feuer E, Midthune D . Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000; 19(3):335-51. DOI: 10.1002/(sici)1097-0258(20000215)19:3<335::aid-sim336>3.0.co;2-z. View

19.

Creamer M, Wang T, Babb S, Cullen K, Day H, Willis G . Tobacco Product Use and Cessation Indicators Among Adults - United States, 2018. MMWR Morb Mortal Wkly Rep. 2019; 68(45):1013-1019. PMC: 6855510. DOI: 10.15585/mmwr.mm6845a2. View

20.

Zhang Y, Vaccarella S, Morgan E, Li M, Etxeberria J, Chokunonga E . Global variations in lung cancer incidence by histological subtype in 2020: a population-based study. Lancet Oncol. 2023; 24(11):1206-1218. DOI: 10.1016/S1470-2045(23)00444-8. View